Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a note issued to investors on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of NASDAQ EGRX opened at $0.70 on Friday. The stock has a market cap of $9.09 million, a price-to-earnings ratio of 0.59 and a beta of 0.51. Eagle Pharmaceuticals has a fifty-two week low of $0.10 and a fifty-two week high of $14.78. The firm’s 50-day simple moving average is $3.35 and its 200 day simple moving average is $4.19.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of hedge funds have recently bought and sold shares of EGRX. Vanguard Group Inc. boosted its stake in shares of Eagle Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after buying an additional 2,630 shares during the last quarter. Headlands Technologies LLC increased its stake in shares of Eagle Pharmaceuticals by 75.7% during the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,861 shares during the last quarter. Mackenzie Financial Corp purchased a new position in Eagle Pharmaceuticals in the second quarter valued at approximately $60,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Eagle Pharmaceuticals during the second quarter valued at $65,000. Finally, Fidelis Capital Partners LLC bought a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at $71,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.